孟鲁司特钠治疗感染后咳嗽的疗效观察

目的探讨孟鲁司特钠治疗感染后咳嗽的疗效。方法收集2012年1月至2013年12月本院呼吸科门诊就诊的感染后咳嗽患者150例，按随机数字表分为观察组（n=75）和对照组（n=75）。对照组给予复方甲氧那明治疗，酌情应用阿奇霉素；观察组在对照组的基础上加用孟鲁司特钠睡前口服，疗程均为2周。比较治疗前后两组患者的日间、夜间及全天咳嗽症状积分，记录与治疗相关的不良反应。结果治疗前观察组和对照组的日间、夜间及全天咳嗽症状积分组间比较，差异均无统计学意义（均P〉0．05）。与治疗前比较，治疗后两组患者日间咳嗽症状积分均显著降低（观察组：0．41±0．25比1．97±0．63，对照组：0．52±0.31比1．82±0．71，均P〈0．05）。治疗后观察组夜间咳嗽症状积分较治疗前明显降低（0．32±0．18比2．01±0．58，P〈O．05），而对照组治疗前后夜间咳嗽症状积分差异无统计学意义（P〉0．05）。与治疗前比较，治疗后两组患者全天咳嗽症状积分均显著降低（观察组：0．73±0．62比3．98±1．25，对照组：1．72±0．98比3．74±1．41，均P〈0．05）。观察组与对照组的不良反应发生率分别为9．3％（7／75）、10．7％（8n5），差异无统计学意义（x2=0．074，P〉O．05）。结论孟鲁司特钠可有效控制感染后咳嗽，尤其是感染后夜间咳嗽。

Efficacy of montelukast in treatment of postinfectious cough

Objective To investigate the efficacy of montelukast in treatment of postinfectious cough. Methods A total of 150 patients with postinfectious cough who visited our respiratory clinic between January 2012 and December 2013 were divided into the observation group （n=75） and control group （n=75） by random number table. The control group was treated with compound methoxyphenamine and as-needed azithromycin. The observation group was treated, based on the control group, with additional montelukast tablets at bedtime. The course of treatment in two groups was 2 weeks. The whole-day, daytime and night- time cough symptom scores were compared between two groups pre- and post- treatment. The treatmentrelated adverse reactions were also recorded. Results Before treatment, there were no differences in whole- day, daytime and nighttime cough symptom scores between two groups （all P〉0.05）. After treatment, patients in both groups showed significant reduction in daytime cough symptom scores compared with baseline （observation group： 0.41±0.25 vs 1.97±0.63, control group： 0.52±0.31 vs 1.82±0.71, both P〈 0.05）. The night-time cough symptom scores were significantly reduced in observation group （0.32±0.18 vs 2.01±0.58, P〈0.05） , but not in control group （P〉0.05）. Compared with baseline, the whole-day cough symptom scores were significantly improved in observation group （0.73 ± 0.62 vs 3.98 ± 1.25） and control group （ 1.72±0.98 vs 3.74±1.41 ） （both P〈0.05 ）. The incidence of adverse reactions was comparable between two groups, with 9.3% （7/75） in observation group and 10.7% （8/75） in control group （X2=0.074, P〉0.05）. Conclusion Montelukast can significantly improve postinfectious cough, especially during the night.